Drug Shortage Report for JAMP REPAGLINIDE
| Report ID | 271009 |
| Drug Identification Number | 02354926 |
| Brand name | JAMP REPAGLINIDE |
| Common or Proper name | Repaglinide Tablets |
| Company Name | JAMP PHARMA CORPORATION |
| Market Status | MARKETED |
| Active Ingredient(s) | REPAGLINIDE |
| Strength(s) | 0.5MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 100 |
| ATC code | A10BX |
| ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2025-10-31 |
| Estimated end date | 2026-02-28 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2025-11-04 |
| Company comments | Allocation |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 1310 RUE NOBEL BOUCHERVILLE, QUEBEC CANADA J4B 5H3 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2025-11-04 | French | Compare |
| v1 | 2025-11-04 | English | Compare |
Showing 1 to 2 of 2